TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11798229
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of opioids
Study: 3044723
Drug: Ajmaline (50‐75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ajmaline (50‐75 mg i.v.)
Study: 3044723
Drug: Lidocaine (100‐200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (100‐200 mg i.v.)
Study: 25746151
Drug: Standard solutions
Normalized name: Stangard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard solutions
Study: 25746151
Drug: Biocompatible solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biocompatible solutions (sensitivity analysis)
Study: 25746151
Drug: Standard solutions
Normalized name: Stangard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard solutions (sensitivity analysis)
Study: 25746151
Drug: Biocompatible solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biocompatible solutions (economic terms)
Study: 21145052
Drug: Erythromycin 125
Normalized name: erythromycin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 125 mg intravenously 30 minutes before endoscopy
Study: 21145052
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered intravenously 30 minutes before endoscopy
Study: 17908562
Drug: Active Individual
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Individual Therapy (AIT) for 5 weeks at 3 hours/week
Study: 17908562
Drug: Active Individual
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Individual Therapy (AIT)
Study: 11223449
Drug: Micronised fenofibrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronised fenofibrate (267 mg/day) for 12 months
Study: 11223449
Drug: Micronised fenofibrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronised fenofibrate (267 mg/day) for 3 months
Study: 11223449
Drug: VLDL-1 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: VLDL-1 (100 microg apoB/ml)
Study: 11223449
Drug: VLDL-1 vs
Approvals — FDA: no, EMA: no, PMDA: no
Description: VLDL-1 vs VLDL-2 at 100 microg apoB/ml
Study: 11223449
Drug: VLDL-1 vs
Approvals — FDA: no, EMA: no, PMDA: no
Description: VLDL-1 vs IDL at 100 microg apoB/ml
Study: 11223449
Drug: Micronised fenofibrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronised fenofibrate (267 mg/day)
Study: 7955804
Drug: Zolpidem (0.21
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem (0.21 mg/kg)
Study: 7955804
Drug: Flumazenil (0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (0.04 mg/kg)
Study: 3296982
Drug: Insulin therapy
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin therapy withdrawn
Study: 3296982
Drug: Control (diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (diet and diabetes education without insulin withdrawal)
Study: 3296982
Drug: Insulin-withdrawal patients
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-withdrawal patients
Study: 27716696
Drug: Expressed breast
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expressed breast milk (EBM; 0.65 kcal/ml)
Study: 24897504
Drug: Prophylactic paracetamol
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic paracetamol treatment (24 hours starting at vaccination)
Study: 24897504
Drug: Therapeutic paracetamol
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic paracetamol treatment (6 hours after vaccination)
Study: 23415202
Drug: Sequential postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential postoperative antibiotic therapy (i.v. and oral)
Study: 14974945
Drug: EC‐MPS (720
Approvals — FDA: no, EMA: no, PMDA: no
Description: EC‐MPS (720 mg b.i.d.)
Study: 14974945
Drug: MMF (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMF (1000 mg b.i.d.)
Study: 10443648
Drug: Alprazolam (0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (0.02 mg/kg, administered orally at 0700 h)
Study: 10443648
Drug: Metyrapone (0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metyrapone (0.04 g/kg, administered orally at 2300 h the night before)
Study: 373906
Drug: Therapy A
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy A (2 AV followed by 2 CMF)
Study: 373906
Drug: Therapy B
Normalized name: Therapy Bayer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy B (2 CMF followed by 2 AV)
Study: 30772980
Drug: Electrical stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrical stimulation combined with biofeedback therapy (6 weeks)
Study: 30772980
Drug: Electrical stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrical stimulation combined with biofeedback therapy
Study: 28758341
Drug: Belatacept 4-weekly
Normalized name: Belatacept
DrugBank: Belatacept (DB06681)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Belatacept 4-weekly
Study: 28758341
Drug: Belatacept 8-weekly
Normalized name: Belatacept
DrugBank: Belatacept (DB06681)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Belatacept 8-weekly
Study: 23446897
Drug: Choline intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choline intake (both 480 mg/d and 930 mg/d)
Study: 19013258
Drug: Bovine collagen
Normalized name: Bovine collagen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine collagen treatment at 15 months
Study: 16963174
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptive (ethinyl estradiol 20 microg plus desogestrel 150 microg)
Study: 15470992
Drug: Experimental Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental Product E (10% carbamide peroxide gel containing potassium nitrate and sodium fluoride)
Study: 9428487
Drug: Single agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single agent chemotherapy (platinum analogue or vinorelbine)
Study: 2721107
Drug: Sublingually administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingually administered buprenorphine (1, 2, and 4 mg)
Study: 2721107
Drug: Subcutaneously administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneously administered buprenorphine (1 and 2 mg)
Study: 1026545
Drug: Cefadroxil, 0.6-1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefadroxil, 0.6-1.8 g per day, given twice or three times daily
Study: 26294136
Drug: Dextromethorphan (DXM)
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextromethorphan (DXM) 120 mg
Study: 26294136
Drug: Guaifenesin 400
Normalized name: guaifenesin 400 MG
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Guaifenesin 400 mg
Study: 22641581
Drug: Vitamin D2
Normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin D2 in small fractionated doses at each HD session, 3 times per week (group D2S)
Study: 21448304
Drug: Dietary supplement
Normalized name: dietary supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplement containing 13 mg p-synephrine and 176 mg caffeine
Study: 21448304
Drug: Dietary supplement
Normalized name: dietary supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplement containing caffeine and p-synephrine
Study: 19653920
Drug: Encapsulated FeSO4
Normalized name: Ferrous Sulfate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Encapsulated FeSO4 (10 mg Fe and 150 microg iodine)
Study: 19653920
Drug: NutraFine RS
Normalized name: (RS)-bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: NutraFine RS (20 mg Fe)
Study: 17468120
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose aspirin (100 mg on alternate days)
Study: 11343977
Drug: Tacrolimus (Tac)
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus (Tac) in combination with mycophenolate mofetil (MMF) and steroids
Study: 11343977
Drug: Cyclosporine (CsA)
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (CsA) in combination with mycophenolate mofetil (MMF) and steroids
Study: 9156357
Drug: Isoprenaline infusion
Normalized name: isoprenaline
DrugBank: Isoprenaline (DB01064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoprenaline infusion (0.1, 0.2, 0.4, 0.75, and 1.5 micrograms/min for 15 min each)
Study: 7701049
Drug: Intravenous (i.v.)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (i.v.) bolus injection of 6 mg benperidol
Study: 7701049
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration as liquid
Study: 7701049
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration as tablets
Study: 3605732
Drug: Diazepam 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 0.15 mg X kg‐1 po
Study: 25898782
Drug: Patient-controlled sedation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled sedation (PCS) with propofol (5 mg bolus doses as needed)
Study: 25898782
Drug: Nurse anesthetist-controlled
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse anesthetist-controlled sedation (ACS) with 2-8 mg/kg/h of propofol
Study: 25898782
Drug: Midazolam (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (control group) with 2-3 mg for induction and additional 1 mg if required
Study: 17217818
Drug: 1-day sodium
Normalized name: ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1-day sodium phosphate bowel preparation
Study: 17217818
Drug: 3-day magnesium
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-day magnesium sulfate bowel preparation
Study: 12959742
Drug: Altered glycoconjugate
Normalized name: sodium bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Altered glycoconjugate metabolism
Study: 10198901
Drug: 50 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/kg/day x 5 days (Group I)
Study: 10198901
Drug: 200 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/kg/day x 5 days (Group II)
Study: 10198901
Drug: 400 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/kg/day x 5 days (Group III)
Study: 10198901
Drug: 200 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/kg/day x 5 days (second treatment for Group I)
Study: 10198901
Drug: 400 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/kg/day x 5 days (second treatment for Group II)
Study: 7774238
Drug: E5 (2
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: E5 (2 mg/kg/day by intravenous infusion 24 hrs apart)
Study: 2195062
Drug: hGH alone
Normalized name: hGH
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: hGH alone (0.1 mg.kg‐1.d‐1)
Study: 2195062
Drug: Prednisone alone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone alone (0.8 mg.kg‐1.d‐1)
Study: 27986344
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (RT) to the lung with doses of 50 to 60 Gy in 10-Gy increments.
Study: 27986344
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (RT) to the left lung.
Study: 25824533
Drug: Exposure and
Normalized name: Anthrax vaccine, adsorbed, pre-exposure and post-exposure prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure and response prevention (EX/RP) therapy
Study: 19847184
Drug: Right-side injection
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Right-side injection of 60 mg papaverine
Study: 19847184
Drug: Left-side injection
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Left-side injection of 60 mg papaverine
Study: 19847184
Drug: Bilateral injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral injection of 30 mg papaverine into each side
Study: 31378980
Drug: Small-quantity lipid-based
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small-quantity lipid-based nutrient supplements (LNS-LNS)
Study: 31378980
Drug: Iron and
Normalized name: beef,iron and wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron and folic acid (IFA) and children received no supplements (IFA-Control)
Study: 29973375
Drug: GX-H9 (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: GX-H9 (0.1 mg/kg weekly)
Study: 29973375
Drug: GX-H9 (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: GX-H9 (0.3 mg/kg EOW)
Study: 29973375
Drug: GX-H9 (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: GX-H9 (0.2 mg/kg EOW)
Study: 29973375
Drug: Genotropin (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotropin (6 µg/kg)
Study: 21038649
Drug: Qishen Huoxue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qishen Huoxue Granules (QHG) + Continuous Renal Replacement Therapy (CRRT)
Study: 12857474
Drug: Continuous Renal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Renal Replacement Therapy (CRRT)
Study: 17058826
Drug: Ganneng Dripping
Normalized name: DRIP COLLECTOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganneng Dripping Pill (GDP)
Study: 12837560
Drug: Topiramate (TPM)
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate (TPM) 200 mg administered rectally
Study: 12837560
Drug: Topiramate (TPM)
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate (TPM) 100 mg administered orally
Study: 12837560
Drug: Topiramate (TPM)
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate (TPM) 200 mg administered orally
Study: 8651472
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium 1% (Tilarin), QID, 1 spray per nostril
Study: 6424997
Drug: Bupropion, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion, 100 mg by mouth three times a day for 9 days
Study: 6424997
Drug: Imipramine, 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine, 25 mg by mouth three times a day for 9 days
Study: 6424997
Drug: Bupropion, 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion, 25 mg/kg subcutaneously for 16 days
Study: 6424997
Drug: Desipramine, 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine, 5 mg/kg subcutaneously for 16 days
Study: 26643793
Drug: Supervised training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised training and home‐based rehabilitation program plus educational‐behavioral therapy
Study: 26643793
Drug: Educational‐behavioral therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational‐behavioral therapy alone
Study: 25509727
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group (oral nimodipine 30 mg three times a day and vinpocetine injection with glucose or saline)
Study: 23043451
Drug: Arginine L-alpha-ketoglutarate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arginine L-alpha-ketoglutarate, methylsulfonylmethane, hydrolyzed type I collagen and bromelain (Group I)
Study: 23043451
Drug: Not applicable
Normalized name: AIR 1000 mL in 1 L NOT APPLICABLE GAS
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not applicable (Group II - no supplement)
Study: 15650645
Drug: Metformin (850
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (850 mg every 8 hours for 7 days)
Study: 10613424
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid mixture solution (L‐arginine hydrochloride 100 mg x kg(‐1) + L‐ornithine hydrochloride 80 mg x kg(‐1) + L‐branched chain amino acids 140 mg x kg(‐1))
Study: 10613424
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid mixture solution (AS)
Study: 7598296
Drug: Naloxone infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone infusions
Study: 30698299
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of amygdalin at 0.6 mg/kg bw
Study: 30698299
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of amygdalin at 3.0 mg/kg bw
Study: 30698299
Drug: Consumption of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consumption of crushed bitter apricot seeds at 60 mg/kg bw
Study: 30698299
Drug: Consumption of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consumption of crushed bitter apricot seeds at 300 mg/kg bw
Study: 30233114
Drug: Integrated yoga
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated yoga therapy module practices, 1 h/day, 5 days a week for 6 weeks
Study: 17394891
Drug: Self etching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self etching priming agent (Xeno III)
Study: 21378375
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated vaccine
Study: 12868045
Drug: AAS self-administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AAS self-administration for 8 weeks
Study: 12868045
Drug: AAS self-administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AAS self-administration for 12-16 weeks
Study: 12868045
Drug: Nandrolone decanoate
Normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nandrolone decanoate (200 mg/wk i.m.) for 8 weeks
Study: 12868045
Drug: AAS administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AAS administration regimen and length of abuse
Study: 1772727
Drug: Subcutaneous suture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous suture including a stitch in the fascia
Study: 1772727
Drug: Subcutaneous suture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous suture not including a stitch in the fascia
Study: 28627976
Drug: Rocuronium administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium administered based on fat-free mass
Study: 28627976
Drug: Rocuronium administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium administered based on real body weight
Study: 24059911
Drug: Alternative artemisinin-based
Normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative artemisinin-based combination therapy
Study: 24059911
Drug: Same first-line
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Same first-line artemisinin-based combination therapy
Study: 20801439
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist inducing a hypogonadic state during IVF-ET cycles
Study: 19694927
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg Udenafil
Study: 19694927
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg Udenafil
Study: 17426277
Drug: 75 microg
Normalized name: Norgestrel 75 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 microg rHA0 vaccine (15 microg H1, 45 microg H3)
Study: 17426277
Drug: 135 microg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 135 microg rHA0 vaccine (45 microg each of H1, H3, B)
Study: 8886414
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg TAK-044
Study: 8886414
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg TAK-044
Study: 26137496
Drug: Mindful awareness
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mindful awareness practices (MAP), 8 weekly sessions
Study: 12407127
Drug: Linezolid 600
Normalized name: linezolid 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid 600 mg twice a day for 7 days
Study: 12407127
Drug: Co-amoxiclav 1000
Normalized name: CO
DrugBank: Carbon monoxide (DB11588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-amoxiclav 1000 mg once a day for 7 days
Study: 8711052
Drug: Group Rational-Emotive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Rational-Emotive Behavior Therapy (9 weekly sessions)
Study: 8711052
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment control group (no intervention during control period)
Study: 1748109
Drug: Branched-chain amino
Normalized name: Branched-chain amino acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branched-chain amino acids (BCAA) supplement during the race
Study: 1748109
Drug: Branched-chain amino
Normalized name: Branched-chain amino acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branched-chain amino acids (BCAA) supplement during the marathon
Study: 2858709
Drug: Tamoxifen 10
Normalized name: tamoxifen 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 10 mg twice daily for two years
Study: 27333088
Drug: Maraviroc (MVC)
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maraviroc (MVC) 150 mg
Study: 22332800
Drug: 15 mg/day
Normalized name: Climara Pro 0.045/0.015 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/day MMI
Study: 22332800
Drug: 30 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/day MMI
Study: 22332800
Drug: 300 mg/day
Normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/day PTU
Study: 19787388
Drug: Limb remote
Approvals — FDA: no, EMA: no, PMDA: no
Description: Limb remote ischemic preconditioning (RIPC) induced twice (24 h and 1 h preoperatively) via three 5‐min cycles of ischemia and reperfusion on the left upper arm using a blood pressure cuff.